Share on StockTwits

LeMaitre Vascular (NASDAQ:LMAT) Director Cornelia W. Lemaitre unloaded 4,700 shares of LeMaitre Vascular stock on the open market in a transaction that occurred on Wednesday, June 25th. The stock was sold at an average price of $8.32, for a total value of $39,104.00. Following the completion of the sale, the director now directly owns 174,581 shares in the company, valued at approximately $1,452,514. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

LeMaitre Vascular (NASDAQ:LMAT) traded down 3.93% during mid-day trading on Monday, hitting $8.0601. 720 shares of the company’s stock traded hands. LeMaitre Vascular has a 1-year low of $6.38 and a 1-year high of $8.96. The stock’s 50-day moving average is $7. and its 200-day moving average is $7.91. The company has a market cap of $126.0 million and a price-to-earnings ratio of 60.36.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.01 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.02 by $0.01. Analysts expect that LeMaitre Vascular will post $0.23 EPS for the current fiscal year.

LMAT has been the subject of a number of recent research reports. Analysts at Stifel Nicolaus initiated coverage on shares of LeMaitre Vascular in a research note on Tuesday, June 24th. They set a “buy” rating and a $11.00 price target on the stock. Finally, analysts at Brean Capital initiated coverage on shares of LeMaitre Vascular in a research note on Monday, May 19th. They set a “buy” rating and a $11.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $10.47.

LeMaitre Vascular, Inc (NASDAQ:LMAT) is a global provider of medical devices and implants for the treatment of peripheral vascular disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.